

07-09-02

PTO/SB/30 Revised (5/20/00)

Applicable for use through xx/xx/xxx OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMBV control number.

RCE/1600
JUL 12 2002
RECEIVED
TECH CENTER 1600/2900

OPI

**REQUEST
FOR
CONTINUED EXAMINATION (RCE)
TRANSMITTAL**

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995.

See The American Inventors Protection Act of 1999 (AIPA).

Application Number	09/352,466
Filing Date	July 13, 1999
First Named Inventor	Virginia C. Broudy
Group / Art Unit	1642
Examiner Name	Helms, L.
Attorney Docket No.	A-195CDDC

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

NOTE: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provision of the AIPA. See Changes to Application Examination and Provisional Application Practice Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice.

1. Submission required under 37 C.F.R. § 1.114

- a. Previously submitted
 - i. Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on _____
(Any unentered amendment(s) referred to above will be entered).
 - ii. Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____
 - iii. Other _____
- b. Enclosed
 - i. Amendment/Reply
 - ii. Affidavit(s)/Declaration(s)
 - iii. Information Disclosure Statement (IDS)
 - iv. Other _____

2. Miscellaneous

- a. Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required)
- b. Other _____


3. Fees The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.

- a. The Commissioner is hereby authorized to charge the following fees, or credit any overpayments to Deposit Account No. 01-0519
 - i. RCE fee required under 37 C.F.R. § 1.17(e) in the amount of \$740.00.
 - ii. Extension of time fee (37 C.F.R. §§ 1.136 and 1.17) in the amount of \$_____.
 - iii. Other _____
- b. Check in the amount of \$_____ is enclosed
- c. Payment by credit card (Form PTO-2038 enclosed)

07/10/2002 CNGUYEN 00000076 010519 09352466

01 FC:179 740.00 CH

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT REQUIRED

NAME (Print/Type)	Robert B. Winter	Registration No. (Attorney/Agent)	34,458
SIGNATURE			
Date:	July 8, 2002		

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service (EL360691173US) under 37 C.F.R. 1.10 on the date indicated below and is addressed to: Assistant Commissioner For Patents, Box RCE, Washington, D.C. 20231.

NAME (Print/Type)			
SIGNATURE		Date:	July 8, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Assistant Commissioner for Patents, Box RCE, Washington, D.C. 20231.



PATENT APPLICATION

TECH CENTER 1600/2900

JUL 12 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Brody et al.

Serial No.: 09/352,466

Group Art Unit No.: 1642

Filed: July 13, 1999

Examiner: Helms, L.

For: Monoclonal Antibodies to Stem Cell Factor Receptors

Docket No.: A-195CDDC

REQUEST FOR CONTINUED EXAMINATION AND AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This is in response to the Advisory Action dated May 21, 2002 in which the rejection of Claim 21 was maintained.

Please amend the application as follows:

In the specification:

Ins DI At page 1, line 1, insert the following: - This application is a continued prosecution application of U.S. Serial No. 09/352,466, filed July 13, 1999, which is a divisional application of U.S. Serial No. 08/255,193, filed June 7, 1994, which is a divisional application of U.S. Serial No. 08/011,078, filed January 29, 1993, which is a continuation application of U.S. Serial No. 07/681,245, filed April 5, 1991. - *C2*

At page 10, replace the first paragraph with the following:

C2 ...HMC-1, [Butterfield et al., Leukemia Research 12:345 (1988)]; bladder carcinoma cell lines 5637 (ATCC HTB9), COS (ATCC CRL 1650), BHK (ATCC CCL 10); the gastric carcinoma cell line KATO3 (ATCC HRB103); the small cell carcinoma lines H69 (ATCC HTB 119), H128 (ATCC HTB 120); and the breast carcinoma cell line DU4475 (ATCC HTB 123), which have been deposited with the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209. Preferred antigens are the human erythroleukemia cell line OCIM1.

EXPRESS MAIL CERTIFICATE

Express Mail mail labeling number:

EL360691173US

Date of Deposit: July 8, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to Assistant Commissioner for Patents, Box RCE, Washington, DC 20231.

Printed Name

Signature